Epilepsy Clinical Trial
Official title:
Human Herpesvirus-6 and Its Effect on the GABA/Glutamate Balance in the Cerebrospinal Fluid and in the Brain From Patients With Epilepsy
This study will explore whether the human herpes virus-6 is associated with epileptic
seizures. The virus may be involved in brain scarring, called mesial temporal sclerosis,
which is seen in some epilepsy patients. The virus is also thought possibly to interfere
with neurotransmitters - chemicals that brain cells use to communicate with each other. This
study will measure levels of two of these chemicals, GABA and glutamate, which are believed
to play a role in the development of seizures.
Patients with epilepsy, with or without mesial temporal sclerosis, and healthy control
subjects 18 years of age and older may be eligible for this study. Control subjects may not
be taking any medication on a regular basis. Epilepsy patients may take only phenytoin,
carbamazepine, oxcarbazepine, lamotrigine, or levetiracetam. Candidates are screened with a
physical examination and blood tests.
Participants have blood drawn and undergo magnetic resonance imaging (MRI) and lumbar
puncture (spinal tap).
Blood Draw
Up to four teaspoons of blood are drawn through a needle in the arm for this study.
MRI
MRI uses a magnetic field and radio waves to produce pictures of the brain. The scanner is a
metal cylinder surrounded by a strong magnetic field. During the scan, the subject lies on a
bed that slides into the cylinder, wearing earplugs to muffle loud noises the machine makes
when the magnetic fields are switched. The scan takes about 90 to 120 minutes, during which
time the subject can communicate with the technician.
Lumbar Puncture
For this test the subject sits upright or lies on his or her side with knees curled at the
chest. A local anesthetic is injected at the lower back, and a needle is inserted in the
space between the bones where the cerebrospinal fluid circulates below the spinal cord. A
small amount of fluid is collected through the needle. Collection of the fluid usually takes
from 5 to 20 minutes.
Objective: We would like to demonstrate with this study that the human herpesvirus-6 plays a
role in the development of mesial temporal sclerosis (MTS) resulting in epilepsy. We would
also like to examine what influence the virus has on the neurotransmitters glutamate and
GABA, since we believe that an imbalance of the major excitatory and inhibitory
neurotransmitters plays an important role in epilepsy.
Study population: The study population will consist of adult patients with epilepsy and MTS
and adult patients with epilepsy and no MTS as confirmed on magnetic resonance (MR) imaging
scan of the brain. We will compare findings in these two groups to those in healthy adult
volunteers.
Design: This is a natural history study in which we will demonstrate the presence or absence
of human herpesvirus-6 in the serum and cerebrospinal fluid (CSF) obtained from each of
three adult study groups: patients with epilepsy and MTS, patients with epilepsy and no MTS,
and normal controls. We will measure in all three groups the concentration of GABA and
glutamate in CSF. In all three groups we will perform proton MR spectroscopy to
non-invasively measure these metabolites in the brain.
Outcome measures: The three subject groups will be compared in terms of the presence or
absence of the human herpesvirus-6 in the serum and CSF and in terms of the levels of
glutamate and GABA as measured in the CSF and by magnetic resonance spectroscopy of the
hippocampus and temporal lobe.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
| Completed |
NCT02909387 -
Adapting Project UPLIFT for Blacks in Georgia
|
N/A | |
| Completed |
NCT05552924 -
Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients
|
N/A | |
| Terminated |
NCT01668654 -
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
|
Phase 3 | |
| Not yet recruiting |
NCT05068323 -
Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients
|
N/A | |
| Completed |
NCT03994718 -
Creative Arts II Study
|
N/A | |
| Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
| Completed |
NCT00782249 -
Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy
|
N/A | |
| Completed |
NCT03683381 -
App-based Intervention for Treating Insomnia Among Patients With Epilepsy
|
N/A | |
| Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
| Active, not recruiting |
NCT06034353 -
Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
|
N/A | |
| Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
| Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
| Not yet recruiting |
NCT05559060 -
Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
|
||
| Completed |
NCT02977208 -
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use
|
Phase 4 | |
| Completed |
NCT02646631 -
Behavioral and Educational Tools to Improve Epilepsy Care
|
N/A | |
| Completed |
NCT02952456 -
Phenomenological Approach of Epilepsy in Patients With Epilepsy
|
||
| Recruiting |
NCT02539134 -
TAK-935 Multiple Rising Dose Study in Healthy Participants
|
Phase 1 | |
| Completed |
NCT02491073 -
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
|
N/A | |
| Terminated |
NCT02757547 -
Transcranial Magnetic Stimulation for Epilepsy
|
N/A |